Ophthalmology prior authorization at Premera Blue Cross
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Premera Blue Cross ophthalmology PA at a glance
Premera Blue Cross reviews ophthalmology PA submissions against its medical policy library, with rules drawn primarily from AAO (American Academy of Ophthalmology) Preferred Practice Patterns. Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet — what to send
- Diagnosis with ICD-10 (nAMD, DME, RVO, mCNV)
- OCT scan with central macular thickness
- Fluorescein angiography or OCT-A confirming CNV/leakage where required
- Prior anti-VEGF history (drug, doses, intervals, response)
- Visual acuity (Snellen + ETDRS letters)
Common denial patterns to pre-empt
Patterns observed in ophthalmology across payers, and where Premera Blue Cross's book of business overlaps:
- Anti-VEGF: brand vs compounded bevacizumab (significant cost differential)
- Step therapy: bevacizumab before aflibercept/faricimab
- Dosing interval not policy-compliant (e.g., monthly vs every-8-weeks)
- Diagnosis confirmation (OCT, fluorescein angiogram) not documented
- Loading dose schedule not followed
Appeal angles when Premera Blue Cross denies
- AAO Preferred Practice Pattern citation
- Anatomic outcome (OCT central macular thickness)
- Functional outcome (visual acuity by ETDRS letters)
- Documented prior anti-VEGF failure
- Diabetic macular edema vs neovascular AMD vs RVO — distinct PA criteria per indication
Peer-to-peer prep
- Bring the latest OCT scan (printed or open in EHR)
- Quote the AAO PPP by year + indication
- For step-therapy through bevacizumab: cite documented failure or contraindication if requesting aflibercept/faricimab first-line
- State whether the dosing is loading (monthly × 3) or maintenance (PRN vs treat-and-extend vs fixed)
Drug-specific PA criteria at Premera Blue Cross
Deep dives on each drug's PA criteria at Premera Blue Cross:
Frequently asked questions
What documentation does Premera Blue Cross need for ophthalmology prior authorizations?
Premera Blue Cross's PA packet for ophthalmology typically includes: Diagnosis with ICD-10 (nAMD, DME, RVO, mCNV); OCT scan with central macular thickness; Fluorescein angiography or OCT-A confirming CNV/leakage where required; Prior anti-VEGF history (drug, doses, intervals, response). AAO (American Academy of Ophthalmology) Preferred Practice Patterns citations strengthen the submission.
What's the turnaround at Premera Blue Cross?
Premera Blue Cross standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which ophthalmology drugs does Premera Blue Cross most often PA-restrict?
Top targets in ophthalmology: aflibercept, faricimab, ranibizumab. Each follows the per-drug step therapy + documentation requirements published in Premera Blue Cross's medical policy library.
How do I prep a peer-to-peer with Premera Blue Cross in ophthalmology?
Bring the latest OCT scan (printed or open in EHR) Quote the AAO PPP by year + indication Have the policy URL and the patient's chart open before the call.
Generate a Ophthalmology PA packet
Open ApprovalHelp — generate a ophthalmology PA packet tailored to Premera Blue Cross's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com